Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Vaccinia virus L1R protein (L1R or L1) is a 250-residue myristoylated transmembrane envelope protein expressed on the surface of the intracellular mature virion (IMV) form, with a 185-residue disulfide-bonded ectodomain (three intramolecular disulfide bonds linking cysteines 34-57, 49-136, and 116-158) and a C-terminal hydrophobic segment embedded in the viral membrane. Its structure, resolved to 1.51 Å, features a bundle of α-helices packed against a pair of two-stranded β-sheets, including a hydrophobic cavity near the N-terminus that shields the myristate moiety essential for virion assembly. L1R is essential for viral replication, cell entry (enabling virion core penetration into the host cytoplasm via lipid mixing), low-pH-triggered cell-cell fusion, and interacts peripherally with the entry/fusion complex (EFC) components like F9, L5, and A28, as well as indirectly with F9. It serves as a potent target for neutralizing antibodies and is a key component of experimental poxvirus vaccines, with structural conservation across orthopoxviruses like monkeypox virus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vaccinia virus L1R protein (L1R).